Case Report
BibTex RIS Cite

Tedavinin Sirolimus’tan Everolimus’a değiştirilmesi sonucu Everolimus’a bağlı pnömonit gelişen bir böbrek transplantasyonu hastası olgusu

Year 2019, Volume: 43 Issue: 1, 37 - 39, 01.07.2019

Abstract

DOI: 10.26650/cjm.2019.43.33 


Pnömonit
mammalian target of rapamycin inhibitörleri tedavisinde görülen bir yan
etkidir. Biz bu olguda tedavinin sirolimustan everolimusa değiştirilmesi sonucu
everolimusa bağlı pnömonit gelişen bir hastayı sunuyoruz. 33 yaşında kadın
hasta tedavisinin sirolimustan everolimusa değiştirilmesinden sonra gelişen
kliniğimize halsizlik, öksürük, gece terlemesi ve yüksek ateş şikayetleriyle
başvurdu. Toraks BT’de buzlu cam görüntüsü ve asiner nodüller görüldü.
Everolimus tedavisi kesildikten sonra hastanın şikayetleri tamamen geriledi.
Sirolimustan everolimusa geçiş sonucu pnömonit daha önce gözlemlenmemiştir.
Everolimus alan hastalarda pulmoner semptomlar gelişirse everolimusa bağlı
pnömonit düşünülmelidir.

Cite this article as: Kaya E, Karakoç A,
Velidedeoğlu M, Pekmezci S, Trabulus S, Seyahi N. A Case of Everolimus Related
Pneumonitis Occurred After Switching Treatment from Sirolimus in a Kidney
Transplant Patient. Cerrahpasa Med J 2019; 43(1): 37-39.

References

  • 1. White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182: 396e403. 2. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009; 115: 2438e46. 3. Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009; 20: 1674e81. 4. Lee HS, Huh KH, Kim YS, Kim MS, Kim HJ, Kim SI, et al. Sirolimus-induced pneumonitis after renal transplantation: a single-center experience. Transplant Proc 2012; 44: 161e3. 5. Morelon E, Stern M, Israël-Biet D, Correas JM, Danel C, Mamzer-Bruneel MF, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patient. Transplantation 2001; 72: 787-90. 6. Haydar AA, Denton M, West A, Rees J, Goldsmith DJ. Sirolimus-induced pneumonitis: three cases and a review of the literature. Am J Transplant 2004; 4: 137-9. 7. Champion L, Stern M, Israël-Biet D, Mamzer-Bruneel MF, Peraldi MN, Kreis H, et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006; 144: 505-9. 8. Cotovio P, Neves M, Santos L, Macário F, Alves R, Mota A. Conversion to everolimus in kidney transplant recipients: to believe or not believe? Transplant Proc 2012; 44: 2966-70. 9. Baas MC, Struijk GH, Moes DJ, van den Berk IA, Jonkers RE, de Fijter JW, et al. Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients. Transpl Int 2014; 27: 428-36. 10. Rehm B, Keller F, Mayer J, Stracke S. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc 2006; 38: 711-3. 11. Singh U. Gupta A. Jasuja S. Sirolimus-induced pneumonitis. Indian J nephrol 2009; 19: 80-1.

A Case of Everolimus Related Pneumonitis Occurred After Switching Treatment from Sirolimus in a Kidney Transplant Patient

Year 2019, Volume: 43 Issue: 1, 37 - 39, 01.07.2019

Abstract

DOI: 10.26650/cjm.2019.43.33 


Pneumonitis is a reported side effect of
treatment with mammalian target of rapamycin inhibitors. In this report, we
present a case of everolimus-related pneumonitis that occurred after treatment
switching from sirolimus to everolimus. A 33-year-old female was admitted to
our clinic with fatigue, cough, night sweats, and high fever after treatment
switching from sirolimus to everolimus. Thorax CT revealed ground-glass
densities and acinar nodules. After withdrawal of everolimus, complete
remission was observed. Pneumonitis after treatment switching from sirolimus to
everolimus has not been observed before. In patients with pulmonary symptoms
during everolimus treatment, drug-related pneumonitis should be considered. 

Cite this article as: Kaya E, Karakoç A,
Velidedeoğlu M, Pekmezci S, Trabulus S, Seyahi N. A Case of Everolimus Related
Pneumonitis Occurred After Switching Treatment from Sirolimus in a Kidney
Transplant Patient. Cerrahpasa Med J 2019; 43(1): 37-39.

References

  • 1. White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182: 396e403. 2. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009; 115: 2438e46. 3. Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009; 20: 1674e81. 4. Lee HS, Huh KH, Kim YS, Kim MS, Kim HJ, Kim SI, et al. Sirolimus-induced pneumonitis after renal transplantation: a single-center experience. Transplant Proc 2012; 44: 161e3. 5. Morelon E, Stern M, Israël-Biet D, Correas JM, Danel C, Mamzer-Bruneel MF, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patient. Transplantation 2001; 72: 787-90. 6. Haydar AA, Denton M, West A, Rees J, Goldsmith DJ. Sirolimus-induced pneumonitis: three cases and a review of the literature. Am J Transplant 2004; 4: 137-9. 7. Champion L, Stern M, Israël-Biet D, Mamzer-Bruneel MF, Peraldi MN, Kreis H, et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006; 144: 505-9. 8. Cotovio P, Neves M, Santos L, Macário F, Alves R, Mota A. Conversion to everolimus in kidney transplant recipients: to believe or not believe? Transplant Proc 2012; 44: 2966-70. 9. Baas MC, Struijk GH, Moes DJ, van den Berk IA, Jonkers RE, de Fijter JW, et al. Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients. Transpl Int 2014; 27: 428-36. 10. Rehm B, Keller F, Mayer J, Stracke S. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc 2006; 38: 711-3. 11. Singh U. Gupta A. Jasuja S. Sirolimus-induced pneumonitis. Indian J nephrol 2009; 19: 80-1.
There are 1 citations in total.

Details

Primary Language Turkish
Subjects Clinical Sciences
Journal Section Olgu Sunumları
Authors

Eda Kaya This is me

Alican Karakoç This is me

Mehmet Velidedeoğlu This is me

Salih Pekmezci This is me

Sinan Trabulus This is me

Nurhan Seyahi

Publication Date July 1, 2019
Published in Issue Year 2019 Volume: 43 Issue: 1

Cite

APA Kaya, E., Karakoç, A., Velidedeoğlu, M., Pekmezci, S., et al. (2019). Tedavinin Sirolimus’tan Everolimus’a değiştirilmesi sonucu Everolimus’a bağlı pnömonit gelişen bir böbrek transplantasyonu hastası olgusu. Cerrahpaşa Tıp Dergisi, 43(1), 37-39.
AMA Kaya E, Karakoç A, Velidedeoğlu M, Pekmezci S, Trabulus S, Seyahi N. Tedavinin Sirolimus’tan Everolimus’a değiştirilmesi sonucu Everolimus’a bağlı pnömonit gelişen bir böbrek transplantasyonu hastası olgusu. Cerrahpaşa Tıp Dergisi. July 2019;43(1):37-39.
Chicago Kaya, Eda, Alican Karakoç, Mehmet Velidedeoğlu, Salih Pekmezci, Sinan Trabulus, and Nurhan Seyahi. “Tedavinin Sirolimus’tan Everolimus’a değiştirilmesi Sonucu Everolimus’a bağlı pnömonit gelişen Bir böbrek Transplantasyonu Hastası Olgusu”. Cerrahpaşa Tıp Dergisi 43, no. 1 (July 2019): 37-39.
EndNote Kaya E, Karakoç A, Velidedeoğlu M, Pekmezci S, Trabulus S, Seyahi N (July 1, 2019) Tedavinin Sirolimus’tan Everolimus’a değiştirilmesi sonucu Everolimus’a bağlı pnömonit gelişen bir böbrek transplantasyonu hastası olgusu. Cerrahpaşa Tıp Dergisi 43 1 37–39.
IEEE E. Kaya, A. Karakoç, M. Velidedeoğlu, S. Pekmezci, S. Trabulus, and N. Seyahi, “Tedavinin Sirolimus’tan Everolimus’a değiştirilmesi sonucu Everolimus’a bağlı pnömonit gelişen bir böbrek transplantasyonu hastası olgusu”, Cerrahpaşa Tıp Dergisi, vol. 43, no. 1, pp. 37–39, 2019.
ISNAD Kaya, Eda et al. “Tedavinin Sirolimus’tan Everolimus’a değiştirilmesi Sonucu Everolimus’a bağlı pnömonit gelişen Bir böbrek Transplantasyonu Hastası Olgusu”. Cerrahpaşa Tıp Dergisi 43/1 (July 2019), 37-39.
JAMA Kaya E, Karakoç A, Velidedeoğlu M, Pekmezci S, Trabulus S, Seyahi N. Tedavinin Sirolimus’tan Everolimus’a değiştirilmesi sonucu Everolimus’a bağlı pnömonit gelişen bir böbrek transplantasyonu hastası olgusu. Cerrahpaşa Tıp Dergisi. 2019;43:37–39.
MLA Kaya, Eda et al. “Tedavinin Sirolimus’tan Everolimus’a değiştirilmesi Sonucu Everolimus’a bağlı pnömonit gelişen Bir böbrek Transplantasyonu Hastası Olgusu”. Cerrahpaşa Tıp Dergisi, vol. 43, no. 1, 2019, pp. 37-39.
Vancouver Kaya E, Karakoç A, Velidedeoğlu M, Pekmezci S, Trabulus S, Seyahi N. Tedavinin Sirolimus’tan Everolimus’a değiştirilmesi sonucu Everolimus’a bağlı pnömonit gelişen bir böbrek transplantasyonu hastası olgusu. Cerrahpaşa Tıp Dergisi. 2019;43(1):37-9.